BL22

(redirected from anti-CD22 immunotoxin)
Also found in: Wikipedia.

BL22

A 63-kDa anti-CD22 recombinant immunotoxin, containing truncated Pseudomonas exotoxin and variable domains from an anti-CD22 antibody. It was effective against hairy cell leukaemia in phase-II trials of patients who had relapse less than 4 years after cladribine therapy.
References in periodicals archive ?
In 2004, the company decided to focus its therapeutic activities on oncology and in December of that year in-licensed two anti-CD22 immunotoxin programs from the National Cancer Institute (NCI) -- GCR-3888 and GCR-8015.
The anti-CD22 immunotoxins GCR-3888 and GCR-8015 comprise a dsFv that targets the CD22 receptor, fused with a specifically engineered toxin molecule that minimizes non-targeted toxicity, resulting in a highly specific, highly potent therapeutic molecule.
Cambridge Antibody acquires oncology product candidates from Genencor
Medical browser ?
Full browser ?